Post by
URLaughable3 on Apr 19, 2018 1:49pm
Someone without 2 toddlers feel free to sharpen the accuracy
NHS crossed the 100k patient mark <br/>
there was a report of NHS generating $10M over 9 months (extrapolated low 12M/yr) <br/>
Pushes the idea there is an avg rev of $120/client per year. Obviously not accurate as most clients came on later in the year, but we will be emeritus and say $150/client/year <br/>
new projected annual rev —> $15M @ 100k clients <br/>
Now some key numbers
projected medical clients to increase by 250k in <br/>
Snn goes to 150k clients (personal achievable prediction haha) to be honest, May already be in that range. <br/>
Insurance plans going to cover medical bud!!!!! Do ppl realize how much demand will increase in the medical market when users aren’t footing the bill?! <br/>
So, increased clients, higher value and fully filled scrips, both increasing NHS revs.. For Example <br/>
150k clients at $250/year in NHS commissions —> $37.5M/yr
<br/> Just trying to put things into a realistic perspective on the value of NHS alone. GL
Comment by
Bluechip2 on Apr 19, 2018 5:59pm
sure, I read 1200-1500/client. Remember there is no Sunniva product available for the medical clients yet, so they require a check up every three months at a cost as well. They are also planning an expansion to the East, so count on another 3-4 clinics minimum
Comment by
URLaughable3 on Apr 19, 2018 6:05pm
That just furthers the point I was trying to make, so thanks blue chip. If NHS turns to 1500 per client at 150k clients that’s $225M/yr lol, our current market cap.. No Brainer if you are looking for aggressive LT gains. NHS at that revenue base would be its own $750M-1B company.
Comment by
Bluechip2 on Apr 19, 2018 6:19pm
good stuff URL3, they are first mover on this strategy I believe. Also, the intangible aspect is to train doctors on cannabis and it's medical benefits so as to direct the treatments towards Sunniva products and impact revenues across the board.
Comment by
URLaughable3 on Apr 20, 2018 9:53am
As a taxpayer, I would love the alternate (weed) being pushed and prescribed over any chemical alternative/competitor. Not only for the cost benefits but also for the long term crutches created by chemical options.